Sarepta Therapeutics (NASDAQ:SRPT) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Sarepta Therapeutics (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday. The biotechnology company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.38 by $0.12, Zacks reports. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%.

Sarepta Therapeutics Trading Down 0.1 %

NASDAQ:SRPT traded down $0.09 during midday trading on Wednesday, reaching $106.86. 1,074,052 shares of the stock traded hands, compared to its average volume of 823,521. The stock has a market capitalization of $10.21 billion, a P/E ratio of 85.49 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a fifty day moving average of $116.73 and a 200 day moving average of $123.01. Sarepta Therapeutics has a 12 month low of $101.15 and a 12 month high of $173.25.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SRPT. Needham & Company LLC restated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Evercore ISI decreased their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Insiders Place Their Bets

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.